Literature DB >> 24888607

Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.

Tae-Jung Kim1, Chan Kwon Park, Chang Dong Yeo, Kihoon Park, Chin Kook Rhee, Jusang Kim, Seung Joon Kim, Sang Haak Lee, Kyo-Young Lee, Hyoung-Kyu Yoon.   

Abstract

BACKGROUND: Simultaneous genotyping has advantages in turnaround time and detecting the real mutational prevalence in unresectable non-small-cell lung cancer (NSCLC), a group not previously genetically characterized.
METHODS: We developed simultaneous panel of screening EGFR and KRAS mutations by direct sequencing or PNA clamping, and ALK rearrangement by fluorescent in situ hybridization (FISH) in multicenter manner.
RESULTS: Of 510 NSCLC Korean patients, simultaneous genotyping identified mutations of EGFR (29.0%) and KRAS (8.6%) and rearrangement of ALK (9.2%). Seven patients had overlaps in mutations. Although several well-known associations between genotypes and clinical characteristics were identified, we found no relationship between ALK rearrangement and sex or smoking history. Unlike the other genotype mutations, ALK rearrangement was associated with advanced disease. Among the ALK-negative group, patients with 10-15% of ALK FISH split shared characteristics, such as younger age and advanced stage disease, more with the ALK-positive group (>15% ALK FISH split) than <10% ALK FISH split group.
CONCLUSIONS: Simultaneous panel genotyping revealed more prevalent ALK rearrangements than reported in previous studies and their strong association with advanced stage irrespective of sex or smoking history. ALK rearrangement seems to be a marker for aggressive tumor biology and should be assessed in advanced disease.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  ALK; EGFR; KRAS; fluorescence in situ hybridization; mutation; non-small-cell lung carcinoma

Mesh:

Substances:

Year:  2014        PMID: 24888607     DOI: 10.1002/jso.23646

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  20 in total

Review 1.  Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.

Authors:  Hyojin Kim; Jin-Haeng Chung
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Epidermal growth factor receptor in non-small cell lung cancer.

Authors:  Charles N Prabhakar
Journal:  Transl Lung Cancer Res       Date:  2015-04

3.  Clinical Characteristics and Outcome of Pathologic N0 Non-small Cell Lung Cancer Patients With False Positive Mediastinal Lymph Node Metastasis on FDG PET-CT.

Authors:  Kyu Yean Kim; Hye Lim Park; Hye Seon Kang; Hwa Young Lee; Ie Ryung Yoo; Sang Haak Lee; Chang Dong Yeo
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

4.  Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocation.

Authors:  Eun Hye Park; Hwa Young Lee; Jin Woo Kim; Chang Dong Yeo
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

5.  Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.

Authors:  SooYoon Sung; Sea-Won Lee; Yoo-Kang Kwak; Jin Hyung Kang; Sook Hee Hong; Yeon-Sil Kim
Journal:  J Neurooncol       Date:  2018-04-11       Impact factor: 4.130

6.  Correlation between combining 18F-FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer.

Authors:  Maomei Ruan; Liu Liu; Lihua Wang; Bei Lei; Xiaoyan Sun; Cheng Chang; Yan Shen; Wenhui Xie
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-01-03       Impact factor: 9.236

7.  CT-guided coaxial biopsy of malignant lung lesions: are cores from 20-gauge needle adequate for histologic diagnosis and molecular analysis?

Authors:  Kyongmin S Beck; Tae-Jung Kim; Kyo Young Lee; Young Kyoon Kim; Jin Hyoung Kang; Dae Hee Han
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

8.  The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order.

Authors:  Guohua Xie; Fang Xie; Ping Wu; Xiangliang Yuan; Yanhui Ma; Yunchuan Xu; Li Li; Ling Xu; Ming Yang; Lisong Shen
Journal:  J Exp Clin Cancer Res       Date:  2015-06-18

9.  Quantitative Multiplexed Proteomics Could Assist Therapeutic Decision Making in Non-Small Cell Lung Cancer Patients with Ambiguous ALK Test Results.

Authors:  Ho Jung An; Eunkyung An; Shahrooz Rabizadeh; Wei-Li Liao; Jon Burrows; Todd Hembrough; Jin Hyung Kang; Chan Kwon Park; Tae-Jung Kim
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

10.  Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Chin Kook Rhee; Yong Hyun Kim; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Sang Haak Lee; Seung Joon Kim; Hyoung Kyu Yoon; Tae-Jung Kim; Kyo Young Lee
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.